Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.
Researchers in this study are assessing the combination of enfortumab vedotin with pembrolizumab immunotherapy in people with bladder cancer that has spread to nearby lymph nodes and will be surgically removed. Both medications are already used to treat bladder cancer, but their use together before surgery is considered investigational. Both drugs help the immune system attack and kill cancer cells. The study investigators will see if this combination treatment can get rid of cancer in the lymph nodes and shrink patients' tumors before surgery.
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and begin to attack them.
Researchers are seeking the best dose of safusidenib erbumine to treat glioma that came back or keeps growing after treatment. The people in this study have glioma with a mutation (change or variant) in a gene called IDH1. Many gliomas have IDH1 mutations, which help cancer cells survive and grow.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Radiation therapy is one of the usual approaches to treating triple-negative breast cancer (TNBC). Researchers think that adding the immunotherapy drug pembrolizumab, with or without olaparib, to radiation therapy may be a better treatment for TNBC than radiation therapy alone.
Researchers want to learn if combining lasofoxifene and abemaciclib works well in people with advanced breast cancer. This treatment will be compared to the usual breast cancer treatment with fulvestrant and abemaciclib. The people in this study have breast cancer that is fueled by estrogen and does not have the HER2 protein. They also have a mutation (change or variant) in the ESR1 gene. Lasofoxifene targets the ESR1 gene mutation.
Mycosis fungoides (MF) is a disease in which lymphocytes (a type of white blood cell) become cancerous and affect the skin, causing "cutaneous T-cell lymphoma." Lymphomatoid papulosis (LyP) is a rare and similar disorder that causes lymphoma-like skin lesions.
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
Researchers are doing this study to see how well COM701 immunotherapy works when used as maintenance therapy for ovarian cancer. Maintenance therapy helps keep cancer from growing again after it shrank or stopped growing following earlier treatment.
